Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2024
0mins
Should l Buy ?
Source: Newsfilter
BNC210 Efficacy in PTSD: Bionomics Limited reported positive results from its Phase 2 ATTUNE study, showing that BNC210 significantly improved PTSD symptoms at Week 12, with effects noted as early as Week 4.
Future Plans for Clinical Trials: The company plans to initiate a Phase 3 study of BNC210 for PTSD in the second half of 2025, while also evaluating it in a separate Phase 3 trial for social anxiety disorder.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
